Published in Ann Oncol on July 05, 2010
Considerations in the development of circulating tumor cell technology for clinical use. J Transl Med (2012) 2.00
Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. Breast Cancer Res (2011) 1.48
Clinical relevance and biology of circulating tumor cells. Breast Cancer Res (2011) 1.34
Epithelial-mesenchymal transition markers expressed in circulating tumor cells in hepatocellular carcinoma patients with different stages of disease. Cell Death Dis (2013) 1.20
Circulating tumor cells in HER2-positive metastatic breast cancer patients: a valuable prognostic and predictive biomarker. BMC Cancer (2013) 1.06
The biological and clinical importance of epithelial-mesenchymal transition in circulating tumor cells. J Cancer Res Clin Oncol (2014) 0.94
Circulating tumor cells in breast cancer patients: an evolving role in patient prognosis and disease progression. Patholog Res Int (2011) 0.94
Progress in circulating tumor cell capture and analysis: implications for cancer management. Expert Rev Mol Diagn (2012) 0.92
Seed, soil, and beyond: The basic biology of brain metastasis. Surg Neurol Int (2013) 0.92
Co-expression of putative stemness and epithelial-to-mesenchymal transition markers on single circulating tumour cells from patients with early and metastatic breast cancer. BMC Cancer (2014) 0.90
Clinical implications of circulating tumor cells of breast cancer patients: role of epithelial-mesenchymal plasticity. Front Oncol (2015) 0.90
First-Line sunitinib in patients with renal cell carcinoma (RCC) in von Hippel-Lindau (VHL) disease: clinical outcome and patterns of radiological response. Fam Cancer (2015) 0.87
Aldehyde dehydrogenase as a marker and functional mediator of metastasis in solid tumors. Clin Exp Metastasis (2015) 0.85
Circulating and disseminated tumor cells from breast cancer patient-derived xenograft-bearing mice as a novel model to study metastasis. Breast Cancer Res (2015) 0.83
Circulating tumor cells in non-metastatic triple-negative breast cancer. Breast Cancer Res Treat (2014) 0.82
Stromal expression of ALDH1 in human breast carcinomas indicates reduced tumor progression. Oncotarget (2015) 0.81
Transcriptional shift identifies a set of genes driving breast cancer chemoresistance. PLoS One (2013) 0.80
The tissue-specific stem cell as a target for chemoprevention. Stem Cell Rev (2011) 0.78
Label-free isolation of a prostate cancer cell among blood cells and the single-cell measurement of drug accumulation using an integrated microfluidic chip. Biomicrofluidics (2015) 0.77
Application of optically-induced-dielectrophoresis in microfluidic system for purification of circulating tumour cells for gene expression analysis- Cancer cell line model. Sci Rep (2016) 0.76
Dynamic changes in numbers and properties of circulating tumor cells and their potential applications. Cancers (Basel) (2014) 0.76
The potential for liquid biopsies in the precision medical treatment of breast cancer. Cancer Biol Med (2016) 0.76
Circulating tumor cells in metastatic breast cancer: the need for a standardized approach. Ann Oncol (2010) 0.75
Promise and limits of the CellSearch platform for evaluating pharmacodynamics in circulating tumor cells. Semin Oncol (2016) 0.75
Isolation of viable cancer cells in antibody-functionalized microfluidic devices. Biomicrofluidics (2014) 0.75
Analysis of circulating tumor cells from lung cancer patients with multiple biomarkers using high-performance size-based microfluidic chip. Oncotarget (2017) 0.75
Profiling protein expression in circulating tumour cells using microfluidic western blotting. Nat Commun (2017) 0.75
Analysis of circulating tumor cells in breast cancer. J Natl Compr Canc Netw (2013) 0.75
Circulating Tumor Cells in Metastatic Breast Cancer: A Prognostic and Predictive Marker. J Patient Cent Res Rev (2014) 0.75
KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer (2009) 3.73
Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol (2001) 3.06
International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Ann Oncol (2010) 2.94
Constitutive activation of NF-kappaB and T-cell leukemia/lymphoma in Notch3 transgenic mice. EMBO J (2000) 2.41
Involvement of p21ras activation in T cell CD69 expression. Eur J Immunol (1994) 1.85
Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study. Ann Oncol (2012) 1.78
Idiosyncratic reaction after oxaliplatin infusion. Ann Oncol (2001) 1.63
Genetic modulation of the Let-7 microRNA binding to KRAS 3'-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecan. Pharmacogenomics J (2010) 1.63
Calcium modulation activates Epstein-Barr virus genome in latently infected cells. Science (1986) 1.61
Expression pattern of notch1, 2 and 3 and Jagged1 and 2 in lymphoid and stromal thymus components: distinct ligand-receptor interactions in intrathymic T cell development. Int Immunol (1999) 1.60
Bone metastases in breast cancer: higher prevalence of osteosclerotic lesions. Radiol Med (2007) 1.58
Expression of chemokine receptors predicts the site of metastatic relapse in patients with axillary node positive primary breast cancer. Ann Oncol (2006) 1.55
Expression of growth factor and chemokine receptors: new insights in the biology of inflammatory breast cancer. Ann Oncol (2007) 1.54
Neoadjuvant concurrent radiochemotherapy in locally advanced (IIIA-IIIB) non-small-cell lung cancer: long-term results according to downstaging. Ann Oncol (2004) 1.51
Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone. J Clin Oncol (1991) 1.49
Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy. Ann Oncol (2011) 1.42
From Erasmus to Socrates: should mobility move from students to teachers? Lancet (1996) 1.39
Prognostic impact of VEGF, CD31, CD34, and CD105 expression and tumour vessel invasion after radical surgery for IB-IIA non-small cell lung cancer. J Clin Pathol (2004) 1.39
Comparison of assay methods for detection of circulating tumor cells in metastatic breast cancer: AdnaGen AdnaTest BreastCancer Select/Detect™ versus Veridex CellSearch™ system. Int J Cancer (2011) 1.38
Validity of flow cytometry for cross-match evaluation in clinical renal transplantation. Nephron (1991) 1.38
Low brain-derived neurotrophic factor (BDNF) levels in serum of Huntington's disease patients. Am J Med Genet B Neuropsychiatr Genet (2007) 1.35
The early growth response gene EGR-1 behaves as a suppressor gene that is down-regulated independent of ARF/Mdm2 but not p53 alterations in fresh human gliomas. Clin Cancer Res (2001) 1.33
Human keratinocyte growth factor activity on proliferation and differentiation of human keratinocytes: differentiation response distinguishes KGF from EGF family. J Cell Physiol (1990) 1.32
Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance? Ann Oncol (2012) 1.28
Bortezomib (VELCADE) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits. Ann Oncol (2006) 1.25
Steroid sensitivity of thymocyte subpopulations during intrathymic differentiation. Effects of 17 beta-estradiol and dexamethasone on subsets expressing T cell antigen receptor or IL-2 receptor. J Immunol (1989) 1.23
Continuous in vivo activation and transient hyporesponsiveness to TcR/CD3 triggering of human gut lamina propria lymphocytes. Eur J Immunol (1993) 1.22
Expression and prognostic significance of LIVIN, SURVIVIN and other apoptosis-related genes in the progression of superficial bladder cancer. Ann Oncol (2003) 1.20
The BFRF1 gene of Epstein-Barr virus encodes a novel protein. J Virol (2000) 1.20
Tissue plasminogen activator controls multiple forms of synaptic plasticity and memory. Eur J Neurosci (2000) 1.18
Pre-treatment neutrophil-to-lymphocyte ratio may be associated with the outcome in patients treated with everolimus for metastatic renal cell carcinoma. Br J Cancer (2013) 1.15
Oxidative stress and ERK1/2 phosphorylation as predictors of outcome in hepatocellular carcinoma patients treated with sorafenib plus octreotide LAR. Cell Death Dis (2011) 1.14
Glucocorticoid receptor-mediated suppression of the interleukin 2 gene expression through impairment of the cooperativity between nuclear factor of activated T cells and AP-1 enhancer elements. J Exp Med (1992) 1.14
Increase of mouse resistance to Candida albicans infection by thymosin alpha 1. Infect Immun (1982) 1.13
Chemokine receptors in advanced breast cancer: differential expression in metastatic disease sites with diagnostic and therapeutic implications. Ann Oncol (2009) 1.12
Localization of Epstein-Barr virus envelope glycoproteins on the inner nuclear membrane of virus-producing cells. J Virol (1989) 1.11
Chemotherapy of advanced non-small-cell lung cancer: a comparison of three active regimens. A randomized trial of the Italian Oncology Group for Clinical Research (G.O.I.R.C.). Ann Oncol (1995) 1.11
Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomised 'GISCAD' trial. Ann Oncol (2010) 1.10
Expression of trKB neurotrophin receptor during T cell development. Role of brain derived neurotrophic factor in immature thymocyte survival. J Immunol (1996) 1.09
Cutting edge: functional role for proline-rich tyrosine kinase 2 in NK cell-mediated natural cytotoxicity. J Immunol (2000) 1.08
Inactivation of the IL-6 gene prevents development of multicentric Castleman's disease in C/EBP beta-deficient mice. J Exp Med (1996) 1.08
Toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms in gastric cancer of intestinal and diffuse histotypes. Clin Exp Immunol (2008) 1.07
Detection of melanoma cells in sentinel lymph nodes by reverse transcriptase-polymerase chain reaction: prognostic significance. Ann Surg Oncol (2004) 1.07
Circulating tumor cells and bone metastases as detected by FDG-PET/CT in patients with metastatic breast cancer. Ann Oncol (2009) 1.07
Increased metastatic lymph node 64 and CYP17 expression are associated with high stage prostate cancer. J Endocrinol (2007) 1.07
Human herpesvirus 6 infection in neoplastic and normal brain tissue. J Med Virol (2001) 1.06
Nuclear and cytoplasmic expression of survivin in 67 surgically resected pancreatic cancer patients. Br J Cancer (2005) 1.05
Human natural killer cells express VLA-4 and VLA-5, which mediate their adhesion to fibronectin. J Immunol (1991) 1.05
Ubiquitination and degradation of Syk and ZAP-70 protein tyrosine kinases in human NK cells upon CD16 engagement. Proc Natl Acad Sci U S A (2001) 1.05
Prognostic value of circulating tumor cells in nonmuscle invasive bladder cancer: a CellSearch analysis. Ann Oncol (2012) 1.05
Identification and characterization of the product encoded by ORF69 of Kaposi's sarcoma-associated herpesvirus. J Virol (2008) 1.04
Gastric pathology in patients with common variable immunodeficiency. Gut (1999) 1.04
Transcription factor Sox11b is involved in spinal cord regeneration in adult zebrafish. Neuroscience (2010) 1.03
Human B-cell immune response to the polymorphic epithelial mucin. Cancer Res (1993) 1.03
Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis. Ann Oncol (2012) 1.03
Cancer stem cells and epithelial-mesenchymal transition: revisiting minimal residual disease. Curr Cancer Drug Targets (2010) 1.03
Differential regulation of miR-21 and miR-146a by Epstein-Barr virus-encoded EBNA2. Leukemia (2012) 1.02
Selective binding of the epidermal growth factor and its specific effects on the epithelial cells of the cornea. Exp Eye Res (1972) 1.02
RAC1/P38 MAPK signaling pathway controls beta1 integrin-induced interleukin-8 production in human natural killer cells. Immunity (2000) 1.02
Transcriptional regulation of the interleukin 2 gene by glucocorticoid hormones. Role of steroid receptor and antigen-responsive 5'-flanking sequences. J Biol Chem (1990) 1.02
Quality of life as a primary end point in oncology. Ann Oncol (2001) 1.02
Second-line chemotherapy for patients with advanced gastric cancer: who may benefit? Br J Cancer (2008) 1.01
Integrin-mediated ras-extracellular regulated kinase (ERK) signaling regulates interferon gamma production in human natural killer cells. J Exp Med (1998) 1.00
The antineoplastic role of bisphosphonates: from basic research to clinical evidence. Ann Oncol (2003) 1.00
Co-localization of multiple ErbB receptors in stratified epithelium of oral squamous cell carcinoma. J Pathol (2001) 1.00
Retinoic acid-induced down-regulation of the interleukin-2 promoter via cis-regulatory sequences containing an octamer motif. Mol Cell Biol (1991) 0.99
Urinary complications from breast cancer metastasis: case report and review of the literature. G Chir (2010) 0.99
Human equilibrative nucleoside transporter 1 (hENT1) protein is associated with short survival in resected ampullary cancer. Ann Oncol (2008) 0.99
Role for the Rac1 exchange factor Vav in the signaling pathways leading to NK cell cytotoxicity. J Immunol (1999) 0.98
Intracellular transport and maturation pathway of human herpesvirus 6. Virology (1999) 0.98
Epstein-Barr virus encoded LMP1 downregulates TCL1 oncogene through miR-29b. Oncogene (2009) 0.98
Proline-rich tyrosine kinase-2 activation by beta 1 integrin fibronectin receptor cross-linking and association with paxillin in human natural killer cells. J Immunol (1997) 0.98
Tumor regression in mesorectal lymphnodes after neoadjuvant chemoradiation for rectal cancer. Eur J Surg Oncol (2007) 0.98
Up-modulation of the expression of functional keratinocyte growth factor receptors induced by high cell density in the human keratinocyte HaCaT cell line. Cell Growth Differ (2000) 0.98
Recommendations for the registration of new chemical entities used in the prevention and treatment of osteoporosis. Calcif Tissue Int (1995) 0.97
Bisphosphonates: new antiangiogenic molecules in cancer treatment? Ann Oncol (2003) 0.97
Epidermal growth factor, somatostatin, and psoriasis. Lancet (1983) 0.97
CD44 triggering enhances human NK cell cytotoxic functions. J Immunol (1994) 0.97
Prevalence of papillomavirus, Epstein-Barr virus, cytomegalovirus, and herpes simplex virus type 2 in urinary bladder cancer. J Med Virol (1998) 0.96
Alterations of microsatellites in neurofibromas of von Recklinghausen's disease. Cancer Res (1995) 0.96
Role of KRAS let-7 LCS6 SNP in metastatic colorectal cancer patients. Ann Oncol (2010) 0.96
Evidence for nuclear internalization of exogenous DNA into mammalian sperm cells. Mol Reprod Dev (1993) 0.96
The mechanism of action of the epidermal growth factor. 3. Stimulation of the uptake of labeled precursors into RNA, DNA and proteins induced by EGF in isolated tumor cells. Hormones (1972) 0.96
Alteration of growth and differentiation factors response by Kirsten and Harvey sarcoma viruses in the IL-3-dependent murine hematopoietic cell line 32D C13(G). Oncogene (1989) 0.96
Gene expression profiles of inflammatory breast cancer: correlation with response to neoadjuvant chemotherapy and metastasis-free survival. Ann Oncol (2013) 0.96
Correlation of p53 and bcl-2 expression with vascular endothelial growth factor (VEGF), microvessel density (MVD) and clinico-pathological features in colon cancer. Cancer Lett (2004) 0.96